Three-arm noninferiority trials with a prespecified margin for inference of the difference in the proportions of binary endpoints.

Abstract:

:The design of a three-arm trial including the experimental treatment, an active reference treatment, and a placebo is recommended as a useful approach to the assessment of noninferiority of the experimental treatment. The inclusion of the placebo arm enables the assessment of assay sensitivity and internal validation, in addition to testing the noninferiority of the experimental treatment to the reference. Generally, the acceptable noninferiority margin Δ has been defined as the maximum clinically irrelevant difference between treatments in many two-arm noninferiority trials. However, many articles have considered a design in which the noninferiority margin Δ is relatively defined as a prespecified fraction f of the unknown effect size of the reference treatment. Therefore, these methods cannot be applied to cases where the margin is defined as a prespecified difference between treatments. In this article, we propose score-based statistical procedures for a three-arm noninferiority trial with a prespecified margin Δ for inference of the difference in the proportions of binary endpoints. In addition, we derive the approximate sample size and optimal allocation to minimize the total sample size and that of the placebo arm. A randomized controlled trial on major depressive disorder based on the difference in the proportions of remission is used to demonstrate our proposed method.

journal_name

J Biopharm Stat

authors

Hida E,Tango T

doi

10.1080/10543406.2013.789893

subject

Has Abstract

pub_date

2013-01-01 00:00:00

pages

774-89

issue

4

eissn

1054-3406

issn

1520-5711

journal_volume

23

pub_type

杂志文章
  • An Evaluation of Statistical Methods for Analyzing Follow-Up Gaussian Laboratory Data with a Lower Quantification Limit.

    abstract::Laboratory data with a lower quantification limit (censored data) are sometimes analyzed by replacing non-quantifiable values with a single value equal to or less than the quantification limit, yielding possibly biased point estimates and variance estimates that are too small. Motivated by a three-period, three-treatm...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.920858

    authors: Karon JM,Wiegand RE,van de Wijgert JH,Kilmarx PH

    更新日期:2015-01-01 00:00:00

  • Design and sample size for evaluating combinations of drugs of linear and loglinear dose-response curves.

    abstract::The study of drug combinations has become important in drug development due to its potential for efficacy at lower, less toxic doses and the need to move new therapies rapidly into clinical trials. The goal is to identify which combinations are additive, synergistic, or antagonistic. Although there exists statistical ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400902964019

    authors: Fang HB,Tian GL,Li W,Tan M

    更新日期:2009-07-01 00:00:00

  • A quality by design approach for longitudinal quality attributes.

    abstract::The concept of quality by design (QbD) as published in ICH-Q8 is currently one of the most recurrent topics in the pharmaceutical literature. This guideline recommends the use of information and prior knowledge gathered during pharmaceutical development studies to provide a scientific rationale for the manufacturing p...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.979197

    authors: Lebrun P,Giacoletti K,Scherder T,Rozet E,Boulanger B

    更新日期:2015-01-01 00:00:00

  • Identification of Risk Factors and Likelihood of Benefit from Adjuvant Chemotherapy for Early Stage Lung Cancer Patients.

    abstract::The purpose of the research is to develop a statistical decision support algorithm for patients who may benefit from Adjuvant Cisplatin/Vinorelbine (ACT) and improve their survival rates. Genome-wide microarray data are used to identify feasible sets of genes and probe sets that constitute the gene signature. The data...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2019.1684310

    authors: Moon H,Chao T,Ahn H

    更新日期:2020-05-03 00:00:00

  • Dose-time-response modeling using negative binomial distribution.

    abstract::People exposed to certain diseases are required to be treated with a safe and effective dose level of a drug. In epidemiological studies to find out an effective dose level, different dose levels are applied to the exposed and a certain number of cures is observed. Negative binomial distribution is considered to fit o...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2013.834916

    authors: Roy M,Choudhury K,Islam MM,Matin MA

    更新日期:2013-01-01 00:00:00

  • Potential use of the scan statistic for quality control in blood product manufacturing.

    abstract::There are minimal standards for the processing of whole blood components, and to apply those standards requires a system of quality assurances. Excessive indications of failures in compliance trigger inspections and other remedial actions, but the demarcation of what is excessive is a critical issue. Issues of low vol...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-200048790

    authors: Lachenbruch PA,Foulkes MA,Williams AE,Epstein JS

    更新日期:2005-01-01 00:00:00

  • Nonparametric tests for evaluation of biosimilarity in variability of follow-on biologics.

    abstract::As more biologic products are going off patent protection, the development of follow-on biologic products (also known as biosimilars) has gained much attention from both the biotechnology industry and regulatory agencies. Unlike small molecules, the development of biologic products is not only more complicated but als...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.941991

    authors: Zhang N,Yang J,Chow SC,Chi E

    更新日期:2014-01-01 00:00:00

  • Assessment of selection bias in estimates of relative bioavailability and intrasubject variability from bioequivalence evaluations.

    abstract::The outcome selection of bioequivalence evaluations for abbreviated new drug applications results in bias towards unity of test-reference ratio estimates, and underestimation of intrasubject variability for the test drug product. In this study, the selection bias in the estimates of testreference ratio and intrasubjec...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-100102503

    authors: Wang Y

    更新日期:2000-08-01 00:00:00

  • A summary statistic for measuring change from baseline.

    abstract::A statistic, W, for measuring change from baseline is developed. Its distribution is found. Simulations using W and analysis of covariance (ANCOVA) are run and the results are compared. W is found to be less powerful than ANCOVA, yet is not seen to suffer some of the ill effects to which ANCOVA can fall prey, namely b...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543409708835187

    authors: Donahue RM

    更新日期:1997-05-01 00:00:00

  • Wilcoxon-Mann-Whitney test: stratify or not?

    abstract::The Wilcoxon-Mann-Whitney (WMW) test is the most commonly used nonparametric method to compare two treatments when the underlying distribution of the outcome variable is not normally distributed. In the presence of stratum effects, the van Elteren (vE) test, a stratified WMW test, can be used to adjust for the stratum...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400802369103

    authors: Qu Y,Zhao YD,Rahardja D

    更新日期:2008-01-01 00:00:00

  • Planning survival studies to compare a treatment to an active control.

    abstract::Rubinstein et al. presented a procedure for determining the required duration of accrual for a clinical trial comparing the survival distributions of two treatments using a classical hypothesis testing formulation. Here their testing procedure is modified in two ways. First, the asymptotic variances used in computatio...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543409308835056

    authors: Bristol DR

    更新日期:1993-09-01 00:00:00

  • Measuring parallelism, linearity, and relative potency in bioassay and immunoassay data.

    abstract::There is often a need to determine parallelism or linearity between pairs of dose-response data sets for various biological applications. This article describes a technique based on a modification of the well-known extra-sum-of-squares principle of statistical regression. The standard extra-sum-of-squares method uses ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-200056532

    authors: Gottschalk PG,Dunn JR

    更新日期:2005-01-01 00:00:00

  • Data-driven analysis strategies for proportion studies in adaptive group sequential test designs.

    abstract::Using multistage adaptive group sequential test designs, the investigator may perform data-driven changes in the design during the course of the trial without inflation of the Type I error rate. This is possible, for example, through the use of the inverse normal method of combining the p-values from the separate stag...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-120024196

    authors: Wassmer G

    更新日期:2003-11-01 00:00:00

  • An equivalence test for the comparison between a test drug and placebo in human abuse potential studies.

    abstract::Statistical methodologies for human abuse potential studies are rarely evaluated. Human abuse potential studies assess whether test drugs produce positive and negative subjective responses on abuse-related measures using volunteers with histories of recreational drug use. These studies typically have a randomized, dou...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2011.616972

    authors: Chen L,Bonson KR

    更新日期:2013-03-11 00:00:00

  • Determining a minimum clinically important difference between treatments for a patient-reported outcome.

    abstract::Patient-reported outcomes are important for assessing the effectiveness of treatments in many disease areas. For this reason, many new instruments that capture patient-reported outcomes have been developed over the past several decades. With the development of each new instrument, there is the ensuing question of what...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400903315757

    authors: Kirby S,Chuang-Stein C,Morris M

    更新日期:2010-09-01 00:00:00

  • Generalized estimating equations for multivariate response with the variates having different distributions.

    abstract::This paper addresses the problem of analyzing multivariate response with the variates having different distributions. We use the generalized estimating equations proposed by Prentice and Zhao (1) to estimate mean and covariance parameters. Wald statistics are used to test hypotheses about the parameters. Data from a t...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543409608835129

    authors: May WL,Johnson WD

    更新日期:1996-05-01 00:00:00

  • Test procedures for disease prevalence with partially validated data.

    abstract::Investigating the prevalence of a disease is an important topic in medical studies. Such investigations are usually based on the classification results of a group of subjects according to whether they have the disease. To classify subjects, screening tests that are inexpensive and nonintrusive to the test subjects are...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2010.544527

    authors: Tang ML,Qiu SF,Poon WY,Tang NS

    更新日期:2012-01-01 00:00:00

  • On the establishment of equivalence acceptance criterion in analytical similarity assessment.

    abstract::For the assessment of biosimilarity of biosimilar products, the United States (US) Food and Drug Administration (FDA) proposed a stepwise approach for providing the totality-of-the-evidence of similarity between a proposed biosimilar product and a US-licensed (reference) product. The stepwise approach starts with the ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2016.1265539

    authors: Wang T,Chow SC

    更新日期:2017-01-01 00:00:00

  • Intent-to-randomize corrections for missing data resulting from run-in selection bias in clinical trials for chronic conditions.

    abstract::In many clinical trials for chronic conditions a run-in period is used prior to randomization. Often, only those participants who meet certain criteria during the run-in phase go on to get randomized. The others, along with the information that they might have provided, are excluded from the study. This exclusion of t...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2011.550107

    authors: Berger VW,Vali B

    更新日期:2011-03-01 00:00:00

  • Mixture-based gatekeeping procedures in adaptive clinical trials.

    abstract::Clinical trials with data-driven decision rules often pursue multiple clinical objectives such as the evaluation of several endpoints or several doses of an experimental treatment. These complex analysis strategies give rise to "multivariate" multiplicity problems with several components or sources of multiplicity. A ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2017.1399901

    authors: Kordzakhia G,Dmitrienko A,Ishida E

    更新日期:2018-01-01 00:00:00

  • Innovative Thinking on Endpoint Selection in Clinical Trials.

    abstract::In clinical trials, selection of appropriate study endpoints is critical for an accurate and reliable evaluation of safety and effectiveness of a test treatment under investigation. In practice, however, there are usually multiple endpoints available for measurement of disease status and/or therapeutic effect of the t...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2019.1657140

    authors: Chow SC,Huang Z

    更新日期:2019-01-01 00:00:00

  • Non-normal random effects models for immunogenicity assay cut point determination.

    abstract::Administration of biological therapeutics can generate undesirable immune responses that may induce anti-drug antibodies (ADAs). Immunogenicity can negatively affect patients, ranging from mild reactive effect to hypersensitivity reactions or even serious autoimmune diseases. Assessment of immunogenicity is critical a...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.972515

    authors: Zhang J,Yu B,Zhang L,Roskos L,Richman L,Yang H

    更新日期:2015-01-01 00:00:00

  • Testing for group structure in high-dimensional data.

    abstract::With the use of finite mixture models for the clustering of a data set, the crucial question of how many clusters there are in the data can be addressed by testing for the smallest number of components in the mixture model compatible with the data. We investigate the performance of a resampling approach to this latter...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2011.608342

    authors: McLachlan GJ,Rathnayake SI

    更新日期:2011-11-01 00:00:00

  • On sample size estimation and re-estimation adjusting for variability in confirmatory trials.

    abstract::Sample size estimation (SSE) is an important issue in the planning of clinical studies. While larger studies are likely to have sufficient power, it may be unethical to expose more patients than necessary to answer a scientific question. Budget considerations may also cause one to limit the study to an adequate size t...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章,评审

    doi:10.1080/10543406.2015.1092031

    authors: Wu PS,Lin M,Chow SC

    更新日期:2016-01-01 00:00:00

  • Flexible stopping boundaries when changing primary endpoints after unblinded interim analyses.

    abstract::It has been widely recognized that interim analyses of accumulating data in a clinical trial can inflate type I error. Different methods, from group sequential boundaries to flexible alpha spending functions, have been developed to control the overall type I error at prespecified level. These methods mainly apply to t...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.901341

    authors: Chen LM,Ibrahim JG,Chu H

    更新日期:2014-01-01 00:00:00

  • Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs.

    abstract::I review the designs available for Phase I dose-finding studies of chemotherapeutic agents in cancer patients. The designs are based on the assumption that both efficacy and toxicity increase with dose, and thus attempt to minimize the number of patients treated at low doses, and also to minimize the chance that patie...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章,评审

    doi:10.1080/10543400600860295

    authors: Potter DM

    更新日期:2006-01-01 00:00:00

  • Nonparametric step-down test procedures for finding minimum effective dose.

    abstract::Nonparametric versions of normal theory step-down multiple-test procedures for inferring minimum effective dose (see Tamhane et al. (1)) were developed and studied by Monte Carlo simulation. Two types of step-down testing procedures were examined. For both procedures, pairwise, linear, or Helmert contrasts of mean ran...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-100101173

    authors: Sidik K,Morris RW

    更新日期:1999-05-01 00:00:00

  • Power approximation for the van Elteren test based on location-scale family of distributions.

    abstract::The van Elteren test, as a type of stratified Wilcoxon-Mann-Whitney test for comparing two treatments accounting for stratum effects, has been used to replace the analysis of variance when the normality assumption was seriously violated. The sample size estimation methods for the van Elteren test have been proposed an...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400600762939

    authors: Zhao YD,Qu Y,Rahardja D

    更新日期:2006-01-01 00:00:00

  • Exact inference for complex clustered data using within-cluster resampling.

    abstract::This paper introduces exact permutation methods for use when there are independent clusters of data with arbitrary within-cluster correlation. To eliminate the problem of clustering, we randomly select a data point from each cluster and for this now independent data, and calculate our test statistic and the associated...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543401003618884

    authors: Follmann D,Fay M

    更新日期:2010-07-01 00:00:00

  • Some Issues of Sample Size Calculation for Time-to-Event Endpoints Using the Freedman and Schoenfeld Formulas.

    abstract::This article deals with seven special issues related to the assumptions, applicability, and practical use of formulas for calculating power or sample size, respectively, for comparative clinical trials with time-to-event endpoints, with particular focus on the well-known Freedman and Schoenfeld methods. All problems a...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.1000546

    authors: Abel UR,Jensen K,Karapanagiotou-Schenkel I,Kieser M

    更新日期:2015-01-01 00:00:00